Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) (NCT07016321)
Emetine for Viral Outbreaks: A Phase 2/3 Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Emetine for Dengue Fever (a.k.a. EVOLVE Antiviral Initiative)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma leakage, severe bleeding, or severe organ involvement)? 2. What are the safety outcomes of emetine, including serious adverse events and toxicities? Participants will be asked to: 1. Take either 6mg emetine, 12mg emetine, or a placebo pill for 7 consecutive days as part of the treatment regimen. 2. Have blood samples taken for at least 5 days to monitor viral load, inflammatory markers, and safety parameters. 3. Be monitored by healthcare staff for daily vital signs and symptoms for clinical assessments for 28 days.
Who can join: Review the eligibility criteria below.
Location: Johns Hopkins University, Division of Infectious Disease — Baltimore, Maryland
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Johns Hopkins University, Division of Infectious Disease — Baltimore, Maryland
- Bharatpur Hospital — Bharatpur-10, Chitwan
📞 Contact the Study Coordinator
Phone: (410) 502-7135
Email: kdorjee1@jhmi.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Dengue
- Improving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility — Havana, La Habana
- Therapeutics for Moderate and Severe Dengue — Chittagong,
- Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean — Fort-de-France,
- A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever — Manaus, Amazonas
- Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection — Piedras Negras, Coahuila
Explore by condition: All Dengue clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.